Risk of infectious diseases and cutaneous tumours in solid organ recipients: A meta-analysis of literature

Table 3 Incidence of fungal infections in solid organ transplant recipients n (%)

Ref.	No. of cases/	Age (yr)	M/F	Median follow-	Therapy	Candida spp	Malassezia	Dermatophytes
	population			up time			furfur
Virgili et al[36]	73/Kidney	22-68	44/29	0.25-26 yr	50.7% association of prednisone, cyclosporine and azathioprine	4 (5.4)	20 (27.4)	7 (9.6)
Güleç et al[37]	102/Kidney	31.9 ± 10.3	68/34	4.5 ± 4.55 yr	38.2% association of prednisone, mycophenolate and cyclosporine	31 (30.4)	37 (36.3)	10 (9.8)
Perera et al[21]	100/Liver	42.5	NA	5.5 (0.75-16) yr	48% association of prednisone and tacrolimus	19%	4%	11%
Lima et al[22]	53/Kidney	44	28/25	NA	83% prednisone 58.5% mycophenolate 50.9% cyclosporine	14 (22.6)	9 (17)	8 (15)

For each literature study has been indicated number of included patients, type of solid organ transplantation, median age, sex, median follow-up time after solid organ transplantation, type of immunosuppressive treatment and the percentage of patients affected by fungal infections. NA: Data non available in the considered study; M: Male; F: Female.